Business
Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
BEDFORD, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes
About this update from Lantheus Holdings, Inc.
[{"type":"text","content":"BEDFORD, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced it will present the following presentations at the upcoming 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, which will be held June 24-27, 2023 in Chicago, Illinois. PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting with PYLARIFY AI on PSMA PET/CT images, including those achieved using PYLARIFY® (piflufolastat F18) PET/CT.1 Standardized PSMA PET reporting provides consistent and precise disease burden quantification in support of patient management and tracking over time.2,3,4 “We're thrilled to present compelling data on the real-world application of AI-enabled PSMA PET imaging at SNMMI,” said Etienne Montagut, Chief Business Officer, Lantheus. “The presentations by Dr. Angellica Gordon from UCLA and Dr. Hong Song from Stanford reflect a significant milestone in our relentless pursuit of advancing prostate cancer management through cutting-edge technology and innovation. By harnessing our deep learning algorithm and extensive datasets, we are committed to sustaining our efforts to improve guidance for prostate cancer patient diagnosis and treatment.” Presentation details are as follows: Date & Time: Sunday, June 25, 2023, 11:00 am – 12:30 pm CTSession Title: Physics, Instrumentation & Data SciencesTitle: Use of aPROMISE as an artificial intelligence software to automate and standardize quantitative heterogeneity of PSMA and FDG PET/CT in patients with mCRPC prior to PSMA radioligand therapy: a proof-of-concept studyPresenter: Angellica Gordon, MD, PGY-3 Nuclear Medicine Resident, UCLAPoster Number: P228 Date & Time: Monday, June 26, 2023, 11:15 am – 12:45 pm CTSession Title: Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies)Title: Total and Anatomically Contextualized Quantitative 18F-DCFPyL PET at biochemical recurrence predicts subsequent biochemical progression free survival in prostate cancer patientsPresenter: Hong Song, MD, Assistant Professor of Radiology (Nuclear Medicine),...